Hayashi et al., 1994 - Google Patents
Synaptic vesicle membrane fusion complex: action of clostridial neurotoxins on assembly.Hayashi et al., 1994
View PDF- Document ID
- 78517894901471946
- Author
- Hayashi T
- McMahon H
- Yamasaki S
- Binz T
- Hata Y
- Südhof T
- Niemann H
- Publication year
- Publication venue
- The EMBO journal
External Links
Snippet
Clostridial neurotoxins inhibit neurotransmitter release by selective and specific intracellular proteolysis of synaptobrevin/VAMP, synaptosomal‐associated protein of 25 kDa (SNAP‐25) or syntaxin. Here we show that in binary reactions synaptobrevin binds weakly to both SNAP …
- 231100000618 Neurotoxin 0 title abstract description 26
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48238—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid
- A61K47/48246—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid drug-peptide, protein or polyamino acid conjugates, i.e. the modifying agent being a protein, peptide, polyamino acid which being linked/complexed to a molecule that being the pharmacologically or therapeutically active agent
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hayashi et al. | Synaptic vesicle membrane fusion complex: action of clostridial neurotoxins on assembly. | |
| Dolly | Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins | |
| Dolly et al. | Neuro-exocytosis: botulinum toxins as inhibitory probes and versatile therapeutics | |
| CA2370289C (en) | Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides | |
| Vaidyanathan et al. | Proteolysis of SNAP‐25 isoforms by botulinum neurotoxin types A, C, and E: domains and amino acid residues controlling the formation of enzyme‐substrate complexes and cleavage | |
| CA2191754C (en) | Modification of clostridial toxins for use as transport proteins | |
| Hayashi et al. | Disassembly of the reconstituted synaptic vesicle membrane fusion complex in vitro. | |
| Humeau et al. | How botulinum and tetanus neurotoxins block neurotransmitter release | |
| US6169074B1 (en) | Peptide inhibitors of neurotransmitter secretion by neuronal cells | |
| Li et al. | A single mutation in the recombinant light chain of tetanus toxin abolishes its proteolytic activity and removes the toxicity seen after reconstitution with native heavy chain | |
| JP2009513118A (en) | Botulinum neurotoxin A protein receptor and use thereof | |
| BRPI0610252A2 (en) | nerve cell carrier | |
| Chaddock et al. | Expression and purification of catalytically active, non-toxic endopeptidase derivatives of Clostridium botulinum toxin type A | |
| NO340732B1 (en) | Transport protein used to introduce chemical compounds into nerve cells | |
| WO2001053336A1 (en) | Clostridial toxin derivatives and methods for treating pain | |
| Dolly et al. | Novel therapeutics based on recombinant botulinum neurotoxins to normalize the release of transmitters and pain mediators | |
| JP2008521423A (en) | Fusion protein | |
| MX2011013014A (en) | Neurotoxins exhibiting shortened biological activity. | |
| Blanes‐Mira et al. | Small peptides patterned after the N‐terminus domain of SNAP25 inhibit SNARE complex assembly and regulated exocytosis | |
| CN110072880A (en) | It is engineered botulic neurotoxin | |
| Blasi et al. | Inhibition of neurotransmitter release by clostridial neurotoxins correlates with specific proteolysis of synaptosomal proteins | |
| AU781226B2 (en) | Isoforms of SNARE molecules and the uses thereof in modulation of cellular exocytosis | |
| Jahn et al. | Botulinum and tetanus neurotoxins: emerging tools for the study of membrane fusion | |
| US5182262A (en) | Calmodulin binding peptide derivatives of non-erythroid alpha spectrin | |
| Li et al. | Expression and characterisation of the heavy chain of tetanus toxin: reconstitution of the fully-recombinant dichain protein in active form |